Genetic determinant of prostate cancer: A review

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A10225034" target="_blank" >RIV/61989592:15110/11:10225034 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Genetic determinant of prostate cancer: A review
Original language description
Background. In prostate cancer, early detection and appropriate treatment remain key approaches. Genetic studies have revealed gene abnormalities which may be specifically associated with the risk of prostate cancer: changes in genes for the androgen receptor, RNAseL, ELAC2, MSR1, BRCA 1 and 2, HPCX, KLF6, HPC20 and fusion genes, e.g. TMPRSS2-ERG). Despite differing research results from molecular biological studies, these techniques can assist in earlier diagnosis enabling timely initiation of treatment. Methods. MEDLINE search was performed to collect articles addressing prostate cancer and genetic risk factors using key words genetics, prostate cancer and risk. Conclusions. A number of potential genetic risk factors/markers has been identified whichmay in near future contribute to earlier diagnosis of PC. Despite many promising data we have found differing results and therefore we suppose further research should be conducted to achieve more precise conclusion.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FJ - Surgery including transplantology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)